{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:20:17Z","timestamp":1790972417075,"version":"4.1.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Discuss prognostic markers for CLL, including ZAP70 expression, IgVH rearrangements, and CD38 expression.Describe the latest chemotherapy regimens for CLL, including combinations containing nucleoside analogues and monoclonal antibodies.Describe appropriate indications for initiation of treatment for CLL.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.11-1-21","type":"journal-article","created":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T19:27:45Z","timestamp":1136834865000},"page":"21-30","source":"Crossref","is-referenced-by-count":41,"title":["Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment"],"prefix":"10.1093","volume":"11","author":[{"given":"Brian L.","family":"Abbott","sequence":"first","affiliation":[{"name":"Leukemia\/Lymphoma Program, University of Colorado Health Science Center, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"2021122208155837800_R1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-113-7-525","article-title":"Chronic lymphocytic leukemia: new insights into biology and therapy","volume":"113","author":"Foon","year":"1990","journal-title":"Ann Intern Med"},{"key":"2021122208155837800_R2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V85.2.307.307","article-title":"Advances in the biology and treatment of B-cell chronic lymphocytic leukemia","volume":"85","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"2021122208155837800_R3","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2003-09-3277","article-title":"Monoclonal CD5+ and CD5\u2212 B-lymphocyte expansions are frequent in the peripheral blood of the elderly","volume":"103","author":"Ghia","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R4","first-page":"148","article-title":"Splenic lymphoma with circulating villous lymphocytes\/splenic marginal-zone lymphoma","volume":"36","author":"Catovsky","year":"1999","journal-title":"Semin Hematol"},{"key":"2021122208155837800_R5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"2021122208155837800_R6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"2021122208155837800_R7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","article-title":"Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance","volume":"62","author":"Montserrat","year":"1986","journal-title":"Br J Haematol"},{"key":"2021122208155837800_R8","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/1097-0142(19871201)60:11<2712::AID-CNCR2820601122>3.0.CO;2-1","article-title":"Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia","volume":"60","author":"Molica","year":"1987","journal-title":"Cancer"},{"key":"2021122208155837800_R9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/sj.leu.2402540","article-title":"Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL)","volume":"16","author":"Faderl","year":"2002","journal-title":"Leukemia"},{"key":"2021122208155837800_R10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000207215","article-title":"Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study","volume":"64","author":"Spati","year":"1980","journal-title":"Acta Haematol"},{"key":"2021122208155837800_R11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.1999.tb01731.x","article-title":"Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia","volume":"62","author":"Molica","year":"1999","journal-title":"Eur J Haematol"},{"key":"2021122208155837800_R12","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"key":"2021122208155837800_R13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"2021122208155837800_R14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1046\/j.1365-2141.2001.03149.x","article-title":"Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia","volume":"115","author":"Jelinek","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122208155837800_R15","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood"},{"key":"2021122208155837800_R16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"2021122208155837800_R17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"2021122208155837800_R18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"2021122208155837800_R19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"key":"2021122208155837800_R20","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122208155837800_R21","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"2021122208155837800_R22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122208155837800_R23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.thj.6200325","article-title":"Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia","volume":"5","author":"Thornton","year":"2004","journal-title":"Hematol J"},{"key":"2021122208155837800_R24","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"2021122208155837800_R25","first-page":"2047","article-title":"Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia","volume":"8","author":"Robertson","year":"1994","journal-title":"Leukemia"},{"key":"2021122208155837800_R26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.1991.9.5.770","article-title":"Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial","volume":"9","author":"Raphael","year":"1991","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R27","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R28","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122208155837800_R29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"key":"2021122208155837800_R30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"2021122208155837800_R31","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-2141.2001.02959.x","article-title":"Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group","volume":"114","author":"Hallek","year":"2001","journal-title":"Br J Haematol"},{"key":"2021122208155837800_R33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1006100900082","article-title":"Phase I\/II evaluation of pentostatin (2\u2032-deoxycoformycin) in a five day schedule for the treatment of relapsed\/refractory B-cell chronic lymphocytic leukaemia","volume":"16","author":"Johnson","year":"1998","journal-title":"Invest New Drugs"},{"key":"2021122208155837800_R34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jnci\/82.17.1416","article-title":"Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer","volume":"82","author":"Ho","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2021122208155837800_R35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122208155837800_R36","first-page":"44","article-title":"Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"27","author":"Waselenko","year":"2000","journal-title":"Semin Oncol"},{"key":"2021122208155837800_R37","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"2021122208155837800_R38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/sj.thj.6200191","article-title":"Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia","volume":"3","author":"Robak","year":"2002","journal-title":"Hematol J"},{"key":"2021122208155837800_R39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncr.11000","article-title":"Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"97","author":"Montillo","year":"2003","journal-title":"Cancer"},{"key":"2021122208155837800_R40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R41","first-page":"324","article-title":"Comparison of cytotoxicity of 2-chloro- 2\u2032-arabino-fluoro-2\u2032-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia","volume":"88","author":"Lindemalm","year":"2003","journal-title":"Haematologica"},{"key":"2021122208155837800_R42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","article-title":"Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia","volume":"103","author":"Tournilhac","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R43","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00277-005-1008-6","article-title":"Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment","volume":"84","author":"Lysak","year":"2005","journal-title":"Ann Hematol"},{"key":"2021122208155837800_R44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20340","article-title":"Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia","volume":"79","author":"Lam","year":"2005","journal-title":"Am J Hematol"},{"issue":"suppl 12","key":"2021122208155837800_R45","first-page":"86","article-title":"High-dose rituximab therapy in chronic lymphocytic leukemia","volume":"6","author":"Keating","year":"2000","journal-title":"Semin Oncol"},{"key":"2021122208155837800_R46","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"2021122208155837800_R48","first-page":"580","article-title":"Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL)","volume":"22","author":"Lamanna","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208155837800_R49","first-page":"580","article-title":"Pentostatin, cyclophosphamide and rituximab (PCR therapy): a new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL)","volume":"22","author":"Weiss","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208155837800_R50","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"2021122208155837800_R51","first-page":"245a","article-title":"The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients","volume":"102","author":"Byrd","year":"2003","journal-title":"Proc Am Soc Hematol"},{"key":"2021122208155837800_R52","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R53","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R54","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0093-7754(03)00253-7","article-title":"Alemtuzumab therapy in B-cell lymphoproliferative disorders","volume":"30","author":"Moreton","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122208155837800_R55","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"2021122208155837800_R56","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R57","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"key":"2021122208155837800_R58","first-page":"101a","article-title":"Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed\/refractory patients with CLL","volume":"104","author":"Weirda","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R59","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R60","first-page":"3555","article-title":"A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia","volume":"9","author":"Frankel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122208155837800_R61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/146532402320219736","article-title":"Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation","volume":"4","author":"Khouri","year":"2002","journal-title":"Cytotherapy"},{"key":"2021122208155837800_R62","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"2021122208155837800_R63","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"2021122208155837800_R64","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","article-title":"Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain genestatus: implications of minimal residual disease measurement with quantitative PCR","volume":"104","author":"Ritgen","year":"2004","journal-title":"Blood"},{"key":"2021122208155837800_R65","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2021122208155837800_R66","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"2021122208155837800_R67","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","article-title":"Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses","volume":"105","author":"Milligan","year":"2005","journal-title":"Blood"},{"key":"2021122208155837800_R68","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0301-472X(02)00828-7","article-title":"CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections","volume":"30","author":"Altes","year":"2002","journal-title":"Exp Hematol"},{"key":"2021122208155837800_R69","first-page":"3176a","article-title":"Combined therapeutic modality with rituximab, fludarabine and cyclophosphamide followed by high dose therapy with autologous stem cell transplantation (ASCT) leads to excellent response rate and high probability of molecular remission in chronic lymphocytic leukemia (CLL) patients","volume":"100","author":"Trneny","year":"2002","journal-title":"Proc Am Soc Hematol"},{"key":"2021122208155837800_R70","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia","volume":"119","author":"Bosch","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122208155837800_R71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.leu.2402752","article-title":"A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211","volume":"17","author":"Byrd","year":"2003","journal-title":"Leukemia"},{"key":"2021122208155837800_R73","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma : low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"2021122208155837800_R74","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","article-title":"Engraftment kinetics after nonmyeloablative allogenic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"2021122208155837800_R75","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.10491","article-title":"Allogeneic blood stem cell transplantation alter a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies","volume":"94","author":"Pedrazzoli","year":"2002","journal-title":"Cancer"},{"key":"2021122208155837800_R76","first-page":"3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic \u00edtem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"Clin Oncol"},{"key":"2021122208155837800_R77","first-page":"2451","article-title":"Map Regimen: A Novel Non-Myeloablative Conditioning Regimen of Mitoxantrone, Ara-C, and Pentostatin (MAP Regimen) for Hematological Malignancies","volume-title":"Proc Am Soc Hematology","author":"Liu","year":"2002"},{"key":"2021122208155837800_R78","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic hymphocytic leukemia after reduced-intensity conditioning and allogeneic stem cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208155837800_R79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V99.1.75","article-title":"Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies","volume":"99","author":"Corradini","year":"2002","journal-title":"Blood"},{"key":"2021122208155837800_R80","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.11-1-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.11-1-21","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/1\/21\/41850631\/oncolo_11_1_21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/1\/21\/41850631\/oncolo_11_1_21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:16:44Z","timestamp":1640179004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/11\/1\/21\/6398162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.11-1-21","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,1,1]]},"published":{"date-parts":[[2006,1,1]]}}}